Procter & Gamble Health Limited (PGHL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Procter & Gamble Health Limited (PGHL) has a cash flow conversion efficiency ratio of 0.278x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs1.72 Billion ≈ $18.63 Million USD) by net assets (Rs6.20 Billion ≈ $67.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Procter & Gamble Health Limited - Cash Flow Conversion Efficiency Trend (2003–2024)
This chart illustrates how Procter & Gamble Health Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Procter & Gamble Health Limited for a breakdown of total debt and financial obligations.
Procter & Gamble Health Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Procter & Gamble Health Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HELIA GROUP LTD.
F:0GI0
|
N/A |
|
Shenzhen Centralcon Investment Holding Co Ltd
SHE:000042
|
0.450x |
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
0.033x |
|
Hangzhou Youngsun Intelligent
SHG:603901
|
0.073x |
|
Shandong Fengyuan Chemical Co Ltd
SHE:002805
|
0.004x |
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
N/A |
|
Nesco Limited
NSE:NESCO
|
0.077x |
|
Harbin Xinguang Optic Electronics
SHG:688011
|
0.001x |
Annual Cash Flow Conversion Efficiency for Procter & Gamble Health Limited (2003–2024)
The table below shows the annual cash flow conversion efficiency of Procter & Gamble Health Limited from 2003 to 2024. For the full company profile with market capitalisation and key ratios, see Procter & Gamble Health Limited market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rs5.37 Billion ≈ $58.07 Million |
Rs1.76 Billion ≈ $19.02 Million |
0.327x | -22.79% |
| 2023-12-31 | Rs5.38 Billion ≈ $58.21 Million |
Rs2.28 Billion ≈ $24.69 Million |
0.424x | +34.94% |
| 2022-12-31 | Rs7.51 Billion ≈ $81.21 Million |
Rs2.36 Billion ≈ $25.52 Million |
0.314x | +14.30% |
| 2021-12-31 | Rs6.16 Billion ≈ $66.67 Million |
Rs1.70 Billion ≈ $18.33 Million |
0.275x | -21.74% |
| 2020-12-31 | Rs7.04 Billion ≈ $76.10 Million |
Rs2.47 Billion ≈ $26.74 Million |
0.351x | +7.61% |
| 2019-12-31 | Rs9.06 Billion ≈ $98.02 Million |
Rs2.96 Billion ≈ $32.00 Million |
0.327x | +485.69% |
| 2018-12-31 | Rs15.40 Billion ≈ $166.56 Million |
Rs-1.30 Billion ≈ $-14.10 Million |
-0.085x | -215.68% |
| 2017-12-31 | Rs7.33 Billion ≈ $79.30 Million |
Rs536.60 Million ≈ $5.80 Million |
0.073x | -55.87% |
| 2016-12-31 | Rs6.45 Billion ≈ $69.80 Million |
Rs1.07 Billion ≈ $11.58 Million |
0.166x | +17.26% |
| 2015-12-31 | Rs5.92 Billion ≈ $63.97 Million |
Rs836.60 Million ≈ $9.05 Million |
0.141x | +1483.68% |
| 2014-12-31 | Rs5.54 Billion ≈ $59.95 Million |
Rs49.50 Million ≈ $535.32K |
0.009x | +937.95% |
| 2013-12-31 | Rs5.23 Billion ≈ $56.56 Million |
Rs4.50 Million ≈ $48.67K |
0.001x | -99.23% |
| 2012-12-31 | Rs4.84 Billion ≈ $52.31 Million |
Rs542.60 Million ≈ $5.87 Million |
0.112x | +280.13% |
| 2011-12-31 | Rs4.10 Billion ≈ $44.35 Million |
Rs-255.40 Million ≈ $-2.76 Million |
-0.062x | -132.70% |
| 2010-12-31 | Rs3.46 Billion ≈ $37.46 Million |
Rs659.70 Million ≈ $7.13 Million |
0.190x | +113.20% |
| 2009-12-31 | Rs4.67 Billion ≈ $50.54 Million |
Rs417.40 Million ≈ $4.51 Million |
0.089x | +936.50% |
| 2008-12-31 | Rs4.51 Billion ≈ $48.82 Million |
Rs38.90 Million ≈ $420.69K |
0.009x | -90.44% |
| 2007-12-31 | Rs4.23 Billion ≈ $45.74 Million |
Rs381.10 Million ≈ $4.12 Million |
0.090x | -56.34% |
| 2006-12-31 | Rs3.93 Billion ≈ $42.50 Million |
Rs811.20 Million ≈ $8.77 Million |
0.206x | -20.21% |
| 2005-12-31 | Rs2.98 Billion ≈ $32.24 Million |
Rs771.20 Million ≈ $8.34 Million |
0.259x | -18.21% |
| 2004-12-31 | Rs2.48 Billion ≈ $26.84 Million |
Rs784.90 Million ≈ $8.49 Million |
0.316x | -14.07% |
| 2003-12-31 | Rs1.96 Billion ≈ $21.22 Million |
Rs722.30 Million ≈ $7.81 Million |
0.368x | -- |
About Procter & Gamble Health Limited
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter … Read more